IDEXX Laboratories Q1 2026: Record Revenue, Growth Guidance

IDEXX Laboratories reported a strong first quarter of 2026, with revenue surging 14% and 11% organically. Their companion animal group diagnostics led the charge, with 11% recurring revenue growth in the U.S. and 12% internationally. They installed 1100 inVue Dx analyzers, boosting instrument sales 28% organically, and earnings per share hit $3.47, up 15%. IDEXX raised full-year revenue guidance to between $4.675 billion and $4.76 billion, with organic revenue now looking like 7.7% to 9.7% and CAG diagnostics recurring at 8.7% to 10.7%. EPS outlook bumped to $14.45 to $14.90, signaling 11% to 15% growth. Pet owners are still prioritizing care for aging animals, and IDEXX outpaced the industry by crushing utilization per visit. New innovations like Cancer Dx launching in Europe and Australia, plus F&A cytology rollout, fueled placements up 12% to 4650 units. Water and livestock segments grew 7% each, software and imaging 11%. Q2 guides 7.3% to 9.3% revenue growth. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/26c9c1cc81824225